Q2FY19 numbers were largely in line with I-direct estimates on operational front. Revenues grew 7.1% YoY to | 4751.4 crore (I-direct estimate: | 4639 crore) due to 26.3% growth in RoW to | 307.5 crore and 17.6% growth in ARV segment to | 244 crore. US revenues grew 6.1% YoY to | 2226.8 crore (I-direct estimate: | 2152.5 crore) EBITDA margins contracted 443 bps YoY to 20.8% mainly due to high base of gRenvela exclusivity. EBITDA declined 11.7% to | 986.2 crore against I-direct estimate of | 964.3 crore...